Crestor aces huge study, says AZ

Some cholesterol med-makers do have reason to rejoice today. AstraZeneca stopped a study of its blockbuster Crestor, saying the pill had already demonstrated clear benefits over placebo. The 15,000-strong study aimed to determine whether Crestor cut the risk of major cardiovascular events in patients without symptoms and with low cholesterol, but with high levels of C-reactive protein, which has been linked to cardiovascular disease.

Analysts said the trial news would give Crestor an edge over its rival--yes, you guessed it--Vytorin. Launched in the U.S. in 2003, Crestor initially lagged, but a 2006 study showing it could hold back the progression of atherosclerosis, and even help shrink arterial plaque, helped it gain market share.

- see AstraZeneca's press release
- read the story in the Wall Street Journal

Related Articles:
It's Crestor vs. Lipitor in AZ trial. Report
AZ hits back at Crestor imitators. Report
FDA hands Crestor a fighting chance. Report
AZ's Crestor flubs key heart failure trial. Report
AZ hit with Crestor patent challenge. Report
Crestor less safe than competing statins. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.